| 0 (0%) | 11-30 07:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.31 | 1-year : | 0.35 |
| Resists | First : | 0.26 | Second : | 0.3 |
| Pivot price | 0.23 |
|||
| Supports | First : | 0.21 | Second : | 0.17 |
| MAs | MA(5) : | 0.22  |
MA(20) : | 0.23 |
| MA(100) : | 0.23 |
MA(250) : | 0.26 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.9 |
D(3) : | 20.8 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 1.07 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ITP ] has closed above bottom band by 42.0%. Bollinger Bands are 13.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.25 - 0.25 | 0.25 - 0.25 |
| Low: | 0.22 - 0.22 | 0.22 - 0.22 |
| Close: | 0.24 - 0.24 | 0.24 - 0.24 |
Tue, 25 Nov 2025
ITP Alum Ari Melenciano Featured in "The Age of Black Metal", an exhibition by Afrotectopia - NYU Tisch School of the Arts
Fri, 21 Nov 2025
Rundown: Four new bright spots on the ITP affordable housing front - Urbanize Atlanta
Thu, 13 Nov 2025
How ITP Taught John That His Voice Matters - Sanofi
Thu, 23 Oct 2025
Novartis Ianalumab Phase 3 Trial Shows Longer Remission in ITP - Docwire News
Wed, 24 Sep 2025
Immune Thrombocytopenia (ITP): Background, Pathophysiology, Etiology - Medscape
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 10 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 3.6 (%) |
| Shares Short | 22 (K) |
| Shares Short P.Month | 40 (K) |
| EPS | -0.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.23 |
| Profit Margin | -14.1 % |
| Operating Margin | 2 % |
| Return on Assets (ttm) | -2.7 % |
| Return on Equity (ttm) | -5.9 % |
| Qtrly Rev. Growth | -12.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 6.93 |
| EBITDA (p.s.) | 0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 8 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -0.24 |
| PEG Ratio | 0 |
| Price to Book value | 0.01 |
| Price to Sales | 0.03 |
| Price to Cash Flow | 0.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|